At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 57 enrolled
Drug / intervention
Dalteparin +1 moredrug
Likely dose
Dalteparin 200 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome
In Brief
A Phase 2 clinical trial evaluating Dalteparin and Apixaban for Nephrotic Syndrome and Thromboembolic Disease. Completed, enrolled 57 participants across 1 site.
Detailed Summary
The study aims to describe the biochemical coagulation profile and investigate the effect of Low molecular weight heparin and Apixaban on this profile in patients with nephrotic syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNephrotic Syndrome, Thromboembolic Disease
CountriesDenmark
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartMar 2021
First PostedApr 2021
Primary CompletionMay 2024
TodayJul 2026
First PostedApr 20, 2021
Enrollment StartMar 25, 2021
Primary CompletionMay 1, 2024
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 5.2 years ago
Interventions
Dalteparindrug
Drug: Dalteparin 200 units/kg once a day for 4-7 days.
Apixabandrug
Drug: Apixaban 5 mg twice a day for 4-7 days.